112 related articles for article (PubMed ID: 1823185)
41. [Novel peptide inhibitors of the myosin light chain kinase suppress hyperpermeability of vascular endothelium].
Marchenko AV; Stepanova EO; Sekridova AV; Sidorova MV; Bushuev VN; Bespalova ZhD; Shirinskiĭ VP
Biofizika; 2010; 55(6):1008-13. PubMed ID: 21268344
[TBL] [Abstract][Full Text] [Related]
42. Hydroxyamino acid specificity of smooth muscle myosin light chain kinase.
Pearson RB; Floyd DM; Hunt JT; Lee VG; Kemp BE
Arch Biochem Biophys; 1988 Jan; 260(1):37-44. PubMed ID: 3341750
[TBL] [Abstract][Full Text] [Related]
43. Structure of the smooth muscle myosin light-chain kinase calmodulin-binding domain peptide bound to calmodulin.
Roth SM; Schneider DM; Strobel LA; VanBerkum MF; Means AR; Wand AJ
Biochemistry; 1991 Oct; 30(42):10078-84. PubMed ID: 1931939
[TBL] [Abstract][Full Text] [Related]
44. Calmodulin antagonists inhibit activity of myosin light-chain kinase independent of calmodulin.
Zimmer M; Hofmann F
Eur J Biochem; 1984 Jul; 142(2):393-7. PubMed ID: 6547673
[TBL] [Abstract][Full Text] [Related]
45. Minimum requirements for inhibition of smooth-muscle myosin light-chain kinase by synthetic peptides.
Hunt JT; Floyd DM; Lee VG; Little DK; Moreland S
Biochem J; 1989 Jan; 257(1):73-8. PubMed ID: 2920029
[TBL] [Abstract][Full Text] [Related]
46. Differential inhibition of cyclic AMP-dependent protein kinase, myosin light chain kinase and protein kinase C by azaacridine and acridine derivatives.
Chen Q; Deady LW; Polya GM
Biol Chem Hoppe Seyler; 1994 Apr; 375(4):223-35. PubMed ID: 8060530
[TBL] [Abstract][Full Text] [Related]
47. Fluorescence energy transfer analysis of calmodulin-peptide complexes.
Chapman ER; Alexander K; Vorherr T; Carafoli E; Storm DR
Biochemistry; 1992 Dec; 31(51):12819-25. PubMed ID: 1463753
[TBL] [Abstract][Full Text] [Related]
48. Protein kinase C pseudosubstrate prototope: structure-function relationships.
House C; Kemp BE
Cell Signal; 1990; 2(2):187-90. PubMed ID: 2400634
[TBL] [Abstract][Full Text] [Related]
49. Activation of myosin light chain kinase and nitric oxide synthase activities by calmodulin fragments.
Persechini A; McMillan K; Leakey P
J Biol Chem; 1994 Jun; 269(23):16148-54. PubMed ID: 7515878
[TBL] [Abstract][Full Text] [Related]
50. Pseudosubstrate sequence may not be critical for autoinhibition of smooth muscle myosin light chain kinase.
Tanaka M; Ikebe R; Matsuura M; Ikebe M
EMBO J; 1995 Jun; 14(12):2839-46. PubMed ID: 7796810
[TBL] [Abstract][Full Text] [Related]
51. Identification of the substrate and pseudosubstrate binding sites of phosphorylase kinase gamma-subunit.
Huang CY; Yuan CJ; Blumenthal DK; Graves DJ
J Biol Chem; 1995 Mar; 270(13):7183-8. PubMed ID: 7706257
[TBL] [Abstract][Full Text] [Related]
52. Role of basic residues in the phosphorylation of synthetic peptides by myosin light chain kinase.
Kemp BE; Pearson RB; House C
Proc Natl Acad Sci U S A; 1983 Dec; 80(24):7471-5. PubMed ID: 6584865
[TBL] [Abstract][Full Text] [Related]
53. Differentiation of the drug-binding sites of calmodulin.
Zimmer M; Hofmann F
Eur J Biochem; 1987 Apr; 164(2):411-20. PubMed ID: 3032617
[TBL] [Abstract][Full Text] [Related]
54. Specific inhibition of cyclic AMP-dependent protein kinase by warangalone and robustic acid.
Wang BH; Ternai B; Polya G
Phytochemistry; 1997 Mar; 44(5):787-96. PubMed ID: 9115691
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of calmodulin-dependent myosin light-chain kinase by growth-hormone-releasing factor and vasoactive intestinal peptide.
Shiraga H; Stallwood D; Ebadi M; Pfeiffer R; Landers D; Paul S
Biochem J; 1994 Jun; 300 ( Pt 3)(Pt 3):901-5. PubMed ID: 8010976
[TBL] [Abstract][Full Text] [Related]
56. MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.--I. Isolation, structural determination and biological properties of MS-271.
Yano K; Toki S; Nakanishi S; Ochiai K; Ando K; Yoshida M; Matsuda Y; Yamasaki M
Bioorg Med Chem; 1996 Jan; 4(1):115-20. PubMed ID: 8689231
[TBL] [Abstract][Full Text] [Related]
57. Phosphorylation of synthetic peptides by skeletal muscle myosin light chain kinases.
Michnoff CH; Kemp BE; Stull JT
J Biol Chem; 1986 Jun; 261(18):8320-6. PubMed ID: 2873140
[TBL] [Abstract][Full Text] [Related]
58. MS-282a and MS-282b, new inhibitors of calmodulin-activated myosin light chain kinase from Streptomyces tauricus ATCC 27470.
Nakanishi S; Kita K; Uosaki Y; Yoshida M; Saitoh Y; Mihara A; Kawamoto I; Matsuda Y
J Antibiot (Tokyo); 1994 Aug; 47(8):855-61. PubMed ID: 7928670
[TBL] [Abstract][Full Text] [Related]
59. Small-angle scattering studies show distinct conformations of calmodulin in its complexes with two peptides based on the regulatory domain of the catalytic subunit of phosphorylase kinase.
Trewhella J; Blumenthal DK; Rokop SE; Seeger PA
Biochemistry; 1990 Oct; 29(40):9316-24. PubMed ID: 2248948
[TBL] [Abstract][Full Text] [Related]
60. Specific inhibition of cyclic AMP-dependent protein kinase by the antimalarial halofantrine and by related phenanthrenes.
Wang BH; Ternai B; Polya GM
Biol Chem Hoppe Seyler; 1994 Aug; 375(8):527-35. PubMed ID: 7811392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
